Article source：Kexing Biopharm
Oct 23,2025
View：
81 As global life sciences enter a new era of innovation, recombinant protein therapeutics have become a key driver in the advancement of biologics. Known for their precision, efficiency, and safety, these therapies are widely used in the treatment of anemia, viral infections, autoimmune diseases, and cancer.
With deep technical expertise and an advanced industrial platform, Kexing Biopharm has become one of China’s leading recombinant protein production bases, playing a vital role in both domestic innovation and international collaboration.
Recombinant protein drugs are produced through genetic engineering technology, allowing for the synthesis of specific proteins outside the human body to replace or modulate physiological functions. These products are highly effective, but their manufacturing requires exceptional capability in:
Stable and scalable expression systems
Large-scale fermentation and purification processes
Strict quality control standards
Regulatory-compliant production environments
That’s why a reliable and mature production base is critical to delivering safe and effective biologics.
As a long-established player in recombinant protein development and manufacturing, Kexing Biopharm offers a fully integrated platform with the following key advantages:
Kexing Biopharm has successfully developed and commercialized a range of recombinant protein therapeutics, including:
Recombinant Human Erythropoietin (rhEPO) – for anemia treatment
Recombinant Interferon α1b – for antiviral and immune modulation
Recombinant Granulocyte Colony-Stimulating Factor (G-CSF) – to treat chemotherapy-induced neutropenia
These offerings position Kexing as a leader in key therapeutic areas such as hematopoiesis, immune regulation, and anti-infection.
Kexing Biopharm operates GMP-certified production plants equipped with:
High-efficiency expression systems (e.g., CHO cells, E. coli)
Automated fermentation, purification, and filling lines
Multi-level cleanroom environments for sterile injectables
Advanced quality control labs (for purity, activity, stability, sterility, etc.)
This infrastructure ensures the consistent quality, scalability, and safety of every product batch.
Kexing Biopharm adheres to strict quality management standards throughout the production process—from raw material sourcing and process controls to final product testing. The platform complies with:
China NMPA regulatory requirements
ICH and WHO quality guidelines
Global standards for biologics in major markets
This commitment to regulatory excellence guarantees that Kexing’s products meet the highest global standards.
Kexing Biopharm maintains an in-house research platform and professional R&D teams focusing on:
Protein structure optimization
Process improvements for expression and purification
Exploration of new indications for clinical application
The company actively collaborates with universities, research institutes, and hospitals, fostering a robust industry-academia-research ecosystem for long-term innovation.
Kexing Biopharm stands as a benchmark enterprise in this field, distinguished by:
A global vision rooted in Shenzhen – Serving both domestic and international markets
Self-owned core technologies – Ensuring supply chain resilience and IP control
Support for high-quality domestic alternatives – Promoting China's biopharma independence
In the evolving landscape of biologics, success depends on technical strength, manufacturing capability, and quality integrity. As one of China’s most established recombinant protein producers, Kexing Biopharm continues to expand its platform, enrich its pipeline, and collaborate with global partners to shape the future of biomedicine.
Interested in learning more about Kexing Biopharm or exploring partnership opportunities in recombinant protein development? Get in touch today to discover the full potential of working with one of China’s top biologics innovators.
BACK TO LIST
Oct 11,2023
